secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001628280-26-029210
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas gets FDA approval for VEPPANU (vepdegestrant) in ESR1m breast cancer; first PROTAC approved
--------------------------------------------------------------------------------

- FDA approved VEPPANU for ER+/HER2-, ESR1-mutated advanced/metastatic breast cancer after at least one prior endocrine therapy.
- VEPPANU is the first FDA-approved PROTAC degrader; approval came before June 5, 2026 PDUFA date.
- Arvinas to receive $50M development milestone payment from collaborator Pfizer upon approval.
- Arvinas and Pfizer on track to select third-party for VEPPANU commercialization.
- Phase 3 VERITAC-2: vepdegestrant reduced risk of progression or death by 43% vs fulvestrant (HR 0.57, p=0.0001).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026029210/0001628280-26-029210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026029210/arvn-20260501.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-029210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer